Leadership is one of our differentiating strengths at AAP. To efficiently execute your project, you require a strong, highly motivated team using the right tools to carry out and interpret results from well-executed experiments. Leadership is the key component that makes all of this happen. At AAP we have the right leadership.
Sreenu graduated in 1995 from the Indian Institute of Chemical Technology (IICT) in Hyderabad, India, where he studied carbohydrate chemistry under the guidance of Dr. Hari Babu Mereyala. After earning his PhD he moved on to do postdoctoral work with Professor Albert Eschenmoser at both the ETH in Zurich, Switzerland and at The Scripps Research Institute in La Jolla, California. He then joined AMRI as a Research Scientist in early 2001and in mid 2005 he relocated back to Hyderabad as Part of the leadership team to establish a new research center for AMRI.
In 2007 Sreenu was hired as a Senior Director of Process R&D at Sai Advantium (now Sai Life Sciences), one of the fastest growing CRO’s in India. While there, Sreenu recruited an impressive staff of senior scientists and fundamentally changed the lab culture by insisting on accountability and project ownership among the R&D.
In late 2008 Sreenu left Sai to found AAP Pharma Technologies India Pvt. Ltd. where he started with 2 chemists and has continued this practice with great success. Now the team has grown to 60 people and counting...
Greg earned his PhD in 1983 at the University of Wisconsin carrying out natural product total synthesis with Professor Edwin Vedejs. He then continued with natural product total synthesis as a postdoc at Harvard University with Professor E. J. Corey. Greg’s first industrial position was as a Scientist in Process R&D at the Upjohn Company, which was followed by his first lab managerial experience as a Department Head in Chemical Development at BMS in Syracuse, NY.
In 1998 Greg left BMS to co-found American Advanced Organics (AAO), a CRO which established a reputation for fast and reliable kilo lab synthesis. During its first two years in operation, AAO successfully completed more than 90 custom synthesis projects, with many of them involving the initial scale up of a synthesis. In 2000, AAO was sold to AMRI, where Greg ultimately relocated to Albany and became Senior Director of Chemical Development. In 2004 Greg became Site Director at the Cambrex Centre for Technical Excellence where he was responsible for contract process R&D and kilo lab GMP synthesis. In late 2005 he accepted a two-year faculty position at Union College and in 2007 he joined Sai Advantium (now Sai Life Sciences) as Senior Vice President of Process and Scale Up. While at Sai, Greg recruited Sreenu for a second time. In 2009 Greg accepted the position of Vice President of Technology at PCI Synthesis (now Seqens) in Massachusetts where he was responsible for R&D, kilo scale GMP synthesis and project management. He left PCI in 2012 to become a consultant to the pharma industry.
Krishna Yalamareddy holds a Ph.D. in Organic Chemistry from the Indian Institute of Chemical Technology (IICT), Hyderabad, where he trained under Dr. A. V. Rama Rao, and completed a post-doctoral fellowship at the University of Texas Southwestern Medical Center, Dallas, TX, with Prof. J. R. Falck. He also holds a Master’s degree in Organic Chemistry from Osmania University, Hyderabad.
Bringing over 25 years of global experience in CRO operations and Process Research & Development, Krishna has held key scientific and leadership roles at organizations including AVRA Laboratories, Curia (formerly Albany Molecular Research Inc.), Corvinus Chemicals LLC (Dallas, TX), Laurus Synthesis, Inc. (Woburn, MA), and ENANTA Pharmaceuticals (Watertown, MA). Before joining AAP Pharma Technologies, he served as President, R&D at Raghava Life Sciences, Hyderabad.
He has authored or co-authored more than twenty scientific publications and continues to drive innovation and excellence in pharmaceutical research and development.
Manoj completed his master’s degree in 2002 from Osmania University, Hyderabad. He has 15 years of potential experience in pharma industry. He started his journey with pharma industry as a Research Scientist trainee at Albany Molecular Research Inc., (AMRI), Hyderabad in 2005 and worked there for 5 years before he moves to AAP on 2010. From 2010, he is working at AAP where he is engaged in the strategic planning, securing on time delivery of high-quality materials, experimental design, optimization of synthesis and purification protocols on lab scale to kilo scale, including process chemistry. Currently he is working as a Group Leader at AAP.
Dr Krishna Kishore K is an accomplished scientist with over 16 years of extensive industrial experience in the CRO, CDMO and API sectors. He holds a Ph.D. in Organic Chemistry from Université de Rennes 1, France, where he conducted his doctoral research under the mentorship of Prof. Michel Vaultier. He also earned a Master’s degree in Organic Chemistry from Osmania University, Hyderabad. Throughout his career, Dr. Kishore has contributed significantly to early-phase drug development, process optimization, and commercial-scale synthesis of APIs and intermediates. Prior to joining AAP Pharma Technologies, he held leadership positions at Raghava Life Sciences, Piramal Pharma Solutions, Sai Life Sciences, Chemveda Life Sciences and Curia (formerly Albany Molecular Research).
Dr. Kishore’s expertise spans a wide range of activities within CRO/CDMO/API operations, including:
• Route scouting and development for early-phase molecules
• Cost-effective scale-up of chemical processes under GMP and non-GMP conditions
• Process development with critical parameter control to meet stringent regulatory specifications
• Drug Master File (DMF) preparation and support for regulatory submissions
He has successfully led cross-functional teams, managing a team of 15 chemists in CRO projects and 5 chemists in API development. His leadership contributed to the successful delivery of several projects in CDMO projects ranging from kilogram to ton scale, including commercial generic APIs and API Intermediates mentioned below: Telmisartan (EP), Alpha Lipoic Acid (EP), Mirabegron, Rebamipide, Ticagrelor, Tenofovir Disoproxil Fumarate, Ifosfamide, Deuruxolitinib, Deucravacitinib, Trofinetide, Zavegepant.
Dr. Kishore’s Ph.D. research was published in Organic Letters journal.
Sumanth completed his master’s degree in analytical chemistry from Andhra University, Vishakhapatnam and later earned his industrial PhD degree from KL University, Andhra Pradesh. He has 20 years of experience in pharma industry where he handled various analytical method development, validation and technology transfer activities. He started his carrier with Dr. Reddy’s laboratories as a chemist in analytical R&D and later worked with generic and service based pharmaceutical companies like Wockhardt, Mylan, Hetero and Sai life sciences. Prior joining AAP in 2022, Sumanth served as head of analytical services and quality control at Therapiva Pvt Ltd, Hyderabad. He has hands on experience in different chromatographic separation techniques and advanced analytical instrumentation. He is well aware of regulatory and quality system requirements. He is currently working as a head of AR&D at AAP where he is instrumental in analytical development support to different phases of drug development programs.
